NYSE:NUVBPharmaceuticals
A Look At Nuvation Bio’s Valuation As EMA Validates Taletrectinib Application In Europe
Eisai and Nuvation Bio (NUVB) just cleared an important hurdle in Europe, with the EMA validating their Marketing Authorisation Application for taletrectinib in advanced ROS1 positive non small cell lung cancer.
See our latest analysis for Nuvation Bio.
Nuvation Bio’s share price has been volatile around the EMA update, with a 1 day share price return of 3.85% decline and a 30 day share price return of 28.09% decline. However, the 1 year total shareholder return of 133.52% and 3 year total...